{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:28:08Z","timestamp":1740130088908,"version":"3.37.3"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Vancomycin is a reference antibiotic against methicillin-resistant staphylococci. Its administration is associated with infusion-related local complications (IRLC). To reduce this risk, it has been proposed to increase vancomycin dilution in the IV bag and to perform continuous infusion using the volumetric pump. The aim of our study was to assess the safety of peripheral infusion of vancomycin with the volumetric pump.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To compare the frequency of IRLC between patients receiving vancomycin and those receiving \u03b2-lactam (BL) antibiotics. Our secondary objective was to assess factors associated with the occurrence of IRLC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and methods<\/jats:title><jats:p>We conducted a prospective observational study in a French tertiary hospital. Between February 2021 and November 2021, we included all patients receiving continuous infusions of vancomycin or BL through a peripherally inserted venous catheter (PIVC). The primary endpoint was the occurrence of IRLC on Day 1 (D1).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We included 168 patients (56 vancomycin, 112 BL). At D1, 14 patients (25%) presented IRLC in the vancomycin group versus 11 patients (10%) in the BL group (P\u200a=\u200a0.01). There was significantly more IRLC in the group receiving vancomycin at an infused concentration above 5 mg\/mL than those receiving BL (8\/15, 53.3% versus 11\/112, 10%, respectively, P\u200a&amp;lt;\u200a0.01). However, no significant difference was observed between patients receiving infused vancomycin concentration \u22645 mg\/mL and patients receiving BL (P\u200a=\u200a0.4).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our data support safe administration of vancomycin if infused at a concentration under 5 mg\/mL, through the volumetric pump on PIVC.<\/jats:p><\/jats:sec>","DOI":"10.1093\/jac\/dkad044","type":"journal-article","created":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T05:09:43Z","timestamp":1677128983000},"page":"1050-1054","source":"Crossref","is-referenced-by-count":2,"title":["Frequency and factors associated with infusion-related local complications of vancomycin on peripheral venous catheters"],"prefix":"10.1093","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9094-7243","authenticated-orcid":false,"given":"Helmi","family":"Ammar","sequence":"first","affiliation":[{"name":"Centre R\u00e9gional de Pharmacovigilance, H\u00f4pital Europ\u00e9en Georges Pompidou, AP-HP , Paris , France"},{"name":"Universit\u00e9 Paris Cit\u00e9 , Paris 75006 , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Rolland","sequence":"additional","affiliation":[{"name":"Service de Microbiologie, Unit\u00e9 Mobile d\u2019Infectiologie, AP-HP, H\u00f4pital Europ\u00e9en Georges Pompidou , 20 rue Leblanc, Paris 75015 , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romain","family":"Jouffroy","sequence":"additional","affiliation":[{"name":"Intensive Care Unit, Ambroise Par\u00e9 Hospital, Assistance Publique H\u00f4pitaux Paris and Paris Saclay University , Boulogne Billancourt , France"},{"name":"EA7329, Institut de Recherche bioM\u00e9dicale et d\u2019Epid\u00e9miologie du Sport, INSEP, Paris University , Paris , France"},{"name":"U1018, Centre de recherche en Epid\u00e9miologie et Sant\u00e9 des Populations, INSERM, Paris Saclay University , Paris , France"},{"name":"EA 7525, Universit\u00e9 des Antilles , Fort de France 97261 , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Dubert","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9 , Paris 75006 , France"},{"name":"Service de Microbiologie, Unit\u00e9 Mobile d\u2019Infectiologie, AP-HP, H\u00f4pital Europ\u00e9en Georges Pompidou , 20 rue Leblanc, Paris 75015 , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Le Beller","sequence":"additional","affiliation":[{"name":"Centre R\u00e9gional de Pharmacovigilance, H\u00f4pital Europ\u00e9en Georges Pompidou, AP-HP , Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Podglajen","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9 , Paris 75006 , France"},{"name":"Service de Microbiologie, AP-HP, H\u00f4pital Europ\u00e9en Georges Pompidou , 20 rue Leblanc, Paris 75015 , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agn\u00e8s","family":"Lillo-Lelouet","sequence":"additional","affiliation":[{"name":"Centre R\u00e9gional de Pharmacovigilance, H\u00f4pital Europ\u00e9en Georges Pompidou, AP-HP , Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Lebeaux","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9 , Paris 75006 , France"},{"name":"Service de Microbiologie, Unit\u00e9 Mobile d\u2019Infectiologie, AP-HP, H\u00f4pital Europ\u00e9en Georges Pompidou , 20 rue Leblanc, Paris 75015 , France"},{"name":"FHU PROTHEE , Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Bensaid","sequence":"additional","affiliation":[{"name":"Service de Microbiologie, Unit\u00e9 Mobile d\u2019Infectiologie, AP-HP, H\u00f4pital Europ\u00e9en Georges Pompidou , 20 rue Leblanc, Paris 75015 , France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,2,23]]},"reference":[{"key":"2023040308032740200_","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/00129804-200309000-00003","article-title":"Vancomycin: new perspectives on an old drug","volume":"26","author":"Hadaway","year":"2003","journal-title":"J Infus Nurs"},{"key":"2023040308032740200_","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"2023040308032740200_","first-page":"391","article-title":"Mechanisms of resistance to daptomycin in Staphylococcus aureus","volume":"30","author":"G\u00f3mez Casanova","year":"2017","journal-title":"Rev Esp Quimioter"},{"key":"2023040308032740200_","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/NAN.0b013e3181cfcee4","article-title":"Intravenous administration issues: a comparison of intravenous insertions and complications in vancomycin versus other antibiotics","volume":"33","author":"Roszell","year":"2010","journal-title":"J Infus Nurs"},{"key":"2023040308032740200_","doi-asserted-by":"crossref","first-page":"251","DOI":"10.5301\/jva.5000220","article-title":"Safe administration of vancomycin through a novel midline catheter: a randomized, prospective clinical trial","volume":"15","author":"Caparas","year":"2014","journal-title":"J Vasc Access"},{"key":"2023040308032740200_","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/jep.12107","article-title":"Infusion phlebitis assessment measures: a systematic review","volume":"20","author":"Ray-Barruel","year":"2014","journal-title":"J Eval Clin Pract"},{"key":"2023040308032740200_","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1128\/AAC.03694-14","article-title":"Influence of vancomycin infusion methods on endothelial cell toxicity","volume":"59","author":"Drouet","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308032740200_","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1128\/AAC.00612-15","article-title":"Endothelial cell toxicity of vancomycin infusion combined with other antibiotics","volume":"59","author":"Drouet","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2023040308032740200_","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1080\/00365540110080908","article-title":"Antibiotics differ in their tendency to cause infusion phlebitis: a prospective observational study","volume":"34","author":"Lanbeck","year":"2002","journal-title":"Scand J Infect Dis"},{"key":"2023040308032740200_","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/978-1-4615-5381-6_160","article-title":"Influence of glycopeptide antibiotics on purine metabolism of endothelial cells","volume":"431","author":"Robibaro","year":"1998","journal-title":"Adv Exp Med Biol"},{"key":"2023040308032740200_","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.medmal.2016.01.010","article-title":"Pr\u00e9paration et administration des antibiotiques par voie injectable\u202f: comment \u00e9viter de jouer \u00e0 l\u2019apprenti sorcier","volume":"46","author":"Longuet","year":"2016","journal-title":"Med Mal Infect"},{"key":"2023040308032740200_","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jiph.2019.09.001","article-title":"Intermittent vs. continuous vancomycin infusion for gram-positive infections: a systematic review and meta-analysis","volume":"13","author":"Chu","year":"2020","journal-title":"J Infect Public Health"},{"key":"2023040308032740200_","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ijantimicag.2015.10.019","article-title":"Continuous versus intermittent infusion of vancomycin in adult patients: a systematic review and meta-analysis","volume":"47","author":"Hao","year":"2016","journal-title":"Int J Antimicrob Agents"},{"author":"emc","key":"2023040308032740200_"},{"key":"2023040308032740200_","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/NAN.0b013e3181f85a73","article-title":"Evaluation of the psychometric properties of the phlebitis and infiltration scales for the assessment of complications of peripheral vascular access devices","volume":"33","author":"Groll","year":"2010","journal-title":"J Infus Nurs"},{"key":"2023040308032740200_","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/NHH.0000000000000481","article-title":"The 2016 infusion therapy standards of practice","volume":"35","author":"Gorski","year":"2017","journal-title":"Home Healthc Now"},{"key":"2023040308032740200_","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/jac\/49.1.155","article-title":"Once-daily versus twice-daily intravenous administration of vancomycin for infections in hospitalized patients","volume":"49","author":"Cohen","year":"2002","journal-title":"J Antimicrob Chemother"},{"author":"Gras","key":"2023040308032740200_","article-title":"Incidence and risk factors for local complications of peripheral venous catheters in patients 80 years and older"},{"key":"2023040308032740200_","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1016\/j.jcrs.2008.08.022","article-title":"Comparison of in vitro safety profiles of vancomycin and cefuroxime on human corneal endothelial cells for intracameral use","volume":"34","author":"Yoeruek","year":"2008","journal-title":"J Cataract Refract Surg"},{"key":"2023040308032740200_","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/jac\/41.2.297","article-title":"Endothelial cell compatibility of glycopeptide antibiotics for intravenous use","volume":"41","author":"Robibaro","year":"1998","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/4\/1050\/49727984\/dkad044.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/4\/1050\/49727984\/dkad044.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T11:07:57Z","timestamp":1701860877000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/78\/4\/1050\/7051649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,23]]},"references-count":20,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,2,23]]},"published-print":{"date-parts":[[2023,4,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkad044","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"type":"print","value":"0305-7453"},{"type":"electronic","value":"1460-2091"}],"subject":[],"published-other":{"date-parts":[[2023,4,4]]},"published":{"date-parts":[[2023,2,23]]}}}